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Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting
anti-ZIKV immunity. Here we report the design and comparative evaluation of four
replication-deﬁcient chimpanzee adenoviral (ChAdOx1) ZIKV vaccine candidates comprising
the addition or deletion of precursor membrane (prM) and envelope, with or without its
transmembrane domain (TM). A single, non-adjuvanted vaccination of ChAdOx1 ZIKV
vaccines elicits suitable levels of protective responses in mice challenged with ZIKV. ChA-
dOx1 prME ΔTM encoding prM and envelope without TM provides 100% protection, as well
as long-lasting anti-envelope immune responses and no evidence of in vitro antibody-
dependent enhancement to dengue virus. Deletion of prM and addition of TM reduces
protective efﬁcacy and yields lower anti-envelope responses. Our ﬁnding that immunity
against ZIKV can be enhanced by modulating antigen membrane anchoring highlights
important parameters in the design of viral vectored ZIKV vaccines to support further clinical
assessments.
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Zika virus (ZIKV) has caused a remarkably explosive out-break in the Americas, with rapid spread to more than 70countries1. Its association of ZIKV with Guillain-Barré
syndrome2, microcephaly in newborns3 and person-to-person
transmission4 underlines the need for an efﬁcacious vaccine
that provides long-lasting anti-ZIKV immunity. Currently, no
licensed Zika vaccines or antivirals are available to prevent
or treat infection. However, exceptional progress has been
made since the World Health Organization declared ZIKV a
public health emergency, notably the description of the ZIKV
atomic structure5,6, the expansion of sequenced genomes of
several ZIKV isolates and in particular the development of pre-
clinical ZIKV challenge models in mice7,8 and in non-human
primates9,10 These models have proven useful to explore efﬁcacy
of many ZIKV vaccine developments and many vaccine platforms
such as subunit envelope protein, virus-like particles (VLP), live
attenuated virus, inactivated virus, naked DNA vaccines,
liposome-encapsulated RNA vaccines and viral vectored-based
vaccines11–15. Equally important, attempts to optimise antigen
secretion and presentation to immune cells include (1) addition
or replacement of ZIKV envelope transmembrane domain to
that of other ﬂavivirus, (2) a great variety of different signal
sequences to improve antigen secretion and (3) addition or
replacement of ZIKV prM for those of other ﬂaviviruses. How-
ever, it is unknown to which extent these subtle and yet non-
uniﬁed modiﬁcations may play a role at maintaining long-lasting
anti-ZIKV immunity.
In the present study we utilise the clinically validated
replication-deﬁcient chimpanzee adenovirus vector (ChAdOx1)
as vaccine platform to express the pre-membrane (prM) and
envelope genes of ZIKV. We demonstrate that immune responses
vary upon the modulation of membrane anchors, in particular the
transmembrane (TM) domain of the envelope and prM. The
ChAdOx1 ZIKV vaccine candidates substantially reduce levels of
viraemia in a challenge with a Brazilian ZIKV isolate in mice,
with highest efﬁcacy resulting in viral vectors expressing the
ZIKV prM and envelope with deletion of the TM domain.
Importantly, no evidence of in vitro antibody-dependent
enhancement (ADE) to dengue is identiﬁed. Owing to the good
safety and immunogenicity proﬁle of the ChAdOx1 platform in
humans and their suitability for high-scale production under
Good Manufacturing Practices (GMP), the ChAdOx1 ZIKV
vaccine is a robust candidate for further clinical assessment.
Results
Antigen design in DNA and ChAdOx1 ZIKV vaccines. Because
the Asian lineage of ZIKV is circulating in the Americas, efforts
have focused on developing an Asian lineage-based vaccine7,9,10.
By November 2015, before the World Health Organization
declared ZIKV an emerging threat, only 5 complete genomes of
Asian lineage were available (Fig. 1a). A year later, at least 47
Asian ZIKV sequences were deposited in the GenBank (Supple-
mentary Fig. 1). Here we used a consensus-based approach to
design cassettes for DNA vaccines and chimpanzee adenoviral
vectored vaccines carrying Asian ZIKV sequences. Percentage
identity of our consensus sequence versus ZIKV genomes was
calculated (Fig. 1b) and a gene cassette was synthesised con-
taining the prM followed by the envelope (E) transgene (prME)
using the Asian consensus sequence (Fig. 1c). We designed
modiﬁed versions of this cassette comprising envelope with
inclusion or deletion of upstream prM (prME or E, respectively)
and addition or deletion of the nucleotides encoding the envelope
C-terminal transmembrane domain, a.a. 729–794 (ΔTM) of
ZIKV (prME ΔTM or Env ΔTM; Fig. 1c); and cloned them into
DNA vaccine plasmids and into ChAdOx1 vaccine platforms.
The expected size of the cloned cassettes was veriﬁed (Fig. 1d)
and ZIKV envelope expression in mammalian cells was con-
ﬁrmed by western immunoblotting (Fig. 1e). We developed four
DNA-based vaccines and four replication-deﬁcient chimpanzee
adenoviral vectored ZIKV vaccines (ChAdOx1 ZIKV).
ZIKV immune responses after vaccination. We performed
immunogenicity assays to identify the most immunogenic can-
didates (Fig. 2). BALB/c mice immunised with a DNA vaccine
using a homologous Prime-Boost (P-B) regimen (Fig. 2a, left)
showed modest anti-ZIKV envelope antibody responses upon
both prime and boost (Fig. 2b, left). In contrast, BALB/c mice
immunised with a single, non-adjuvanted vaccine dose of ChA-
dOx1 (Fig. 2a, right) showed anti-ZIKV envelope antibodies at
2 weeks and peaked at 4 weeks (Fig. 2b, right). Interestingly, our
results indicated that the concomitant inclusion of prM and ΔTM
deletion elicited the highest anti-ZIKV envelope antibody titres
peaking at 4 months post immunisation (Fig. 2b, right). Impor-
tantly, the durability of the anti-ZIKV antibody responses was
maintained in the prME ΔTM-immunised group for up to
9 months, whilst lower antibody titres were observed in groups
receiving the other vaccine candidates (Fig. 2b, right). Vaccine
immunogenicity was also assessed in CD1 mice, conﬁrming the
capacity of the ChAdOx1 vaccines to induce antibody responses
in outbred animals, which was sustained at high levels of antibody
titres over a year, elicited by the same single and non-adjuvanted
dose of ChAdOx1 prME ΔTM (Supplementary Fig. 3a).
T-cell responses were quantiﬁed by ex vivo interferon-γ (IFNγ)
ELISPOT. BALB/c mice receiving DNA vaccines showed modest
T-cell frequencies after stimulation with a pool of ZIKV envelope
peptides both, at 2 weeks each after prime and boost, with the Env
ΔTM group being the most efﬁcient T-cell inducer (Fig. 2c, left).
In contrast, a single immunisation of ChAdOx1 ZIKV vaccines
induced far more robust T-cell responses than DNA vaccines as
early as 2 weeks after prime and remained detectable for at least
3 months (Fig. 2c, right). Overall, T-cell responses to ChAdOx1
vaccines expressing Env, Env ΔTM and their prM counterparts
were similar at week 2, with a trend by ChAdOx1 prME towards
induction of lower T-cell responses. Interestingly, the prME ΔTM
candidate maintained sustained responses at 2 weeks and
3 months after immunisation, indicating its ability to induce a
good T-cell memory response.
Efﬁcacy of ChAdOx1 ZIKV vaccines in a ZIKV challenge
model. We used an Asian ZIKV strain to challenge mice7 for the
assessment of efﬁcacy of the various ChAdOx1 ZIKV vaccines.
BALB/c mice were immunised with non-adjuvanted ChAdOx1
vaccines and challenged 4 weeks later with 100 plaque-forming
units (PFU) of a ZIKV isolated from Brazil (ZIKV-BR). Vaccine
efﬁcacy was measured in blood by ZIKV viral load (VL) using
quantitative reverse transcriptionPCR (RT-qPCR) at several time
points during 7 days (Fig. 3a). Both naive and ChAdOx1 control
groups (Supplementary Fig. 3b) displayed the typical onset of
viraemia with a well-established peak at d3, and all infected mice
were able to clear ZIKV by d77 (Fig. 3b, naive). Mice vaccinated
with the rest of the vaccine candidates (prME, Env and
Env ΔTM) substantially decreased VL but did not afford sterile
protection to all animals in those groups. Importantly, the
ChAdOx1 prME ΔTM vaccine conferred complete protection
against ZIKV-BR challenge with no detectable viraemia at any
time point (Fig. 3b). Additional parameters reﬂecting vaccine
efﬁcacy were assessed, such as an analysis of 50-fold reduction
in viraemia since day 1 after ZIKV challenge and reduction of
viraemia peak at day 3 (Fig. 3c). These parameters can inform on
the various capacity levels of ChAdOx1 ZIKV vaccines to confer
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protection in this challenge model, indicating that the ChAdOx1
prME ΔTM is superior to the other vaccine candidates.
As in previous reports, anti-ZIKV envelope antibodies prior to
the mouse challenge were quantiﬁed by enzyme-linked immu-
nosorbent assay (ELISA) and reciprocal titres were calculated for
each vaccinated group (Supplementary Fig. 4). This provided
conﬁrmation under different laboratory conditions and in a
blinded ZIKV challenge study that the deletion of TM played an
important role in the production of high antibody titres able to
bind the ZIKV structural antigen. A comparison of the levels of
ZIKV envelope antibody titres against the ZIKV-BR VL from all
animals and all vaccine candidates under the study (Fig. 3d)
revealed that an endpoint titre ≥ 3 was indicative of the strongest
reduction of VL after the ZIKV-BR challenge (Fig. 3d, left),
whereas prME and Env (Fig. 3d, right) presented endpoint
titres < 3 that were related to a partial vaccine protection,
although with a substantial decrease of VL of several log fold.
ZIKV antigen secretion by membrane-anchoring components.
Although the anti-envelope antibodies elicited by ChAdOx1 prME
were detectable, those induced by the counterpart vaccine ChA-
dOx1 prME ΔTM were signiﬁcantly higher (Fig. 3e, left). Similar
ﬁndings were observed in the ChAdOx1 Env ΔTM vaccine with
greater antibody-binding activity to ZIKV envelope when com-
pared to the ChAdOx1 Env (Fig. 3e, right). These data suggest that
presence of the envelope transmembrane domain impairs anti-
body production elicited by our adenoviral vector. In an attempt
to explain the differential immunogenicity among the ChAdOx1
ZIKV vaccine candidates, the subcellular localisation of the
endogenously expressed vaccine antigen was explored by immu-
noﬂuorescence (IF) using a monoclonal anti-ﬂavivirus antibody
48 h after transfection (Fig. 3f). We detected differential staining
with brighter positive signals across the cytoplasmic compartment
in the vaccines expressing prME and Env, when compared to their
counterparts prME ΔTM, that showed positive signal mainly
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Fig. 1 Zika vaccine design. a A phylogenetic tree for ZIKV genomes up to November 2015; blue and red labels represent the African and Asian lineages of
ZIKV, respectively. b Conservation homology of an Asian consensus sequence versus all genomic sequences depicted in Supplementary Fig. 1. The circle
represents the ZIKV-BR strain used for the challenge experiment. c Schematic representation of the Zika immunogen versions used in this study; red box
represents the tPA leading sequence. d Restriction enzyme analysis of the plasmid DNA vaccine constructs that were further cloned into ChAdOx1 vector;
a 3.3 kb band size represents the DNA vaccine plasmid back bone. e Expression of ZIKV immunogens by western immunoblotting using an anti-ZIKV
envelope antibody. M molecular marker, C control, E empty plasmid. Uncropped images are shown in Supplementary Fig. 2
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around the nucleus and with punctuate patterns across the cyto-
plasmic compartment and for Env ΔTM, with less bright staining
around the nucleus. Furthermore, we have assessed the presence
of the ZIKV envelope antigen in transfected cells in both, the
intracellular compartment and the supernatant (Fig. 3g and
Supplementary Figs. 5, 9 and 10). HEK-293 cells expressing prME
ΔTM and Env ΔTM antigens secreted ZIKV envelope to the
culture supernatant with higher efﬁciency than their counterparts
Env and prME, with prME ΔTM secreting with highest efﬁciency
in vitro (Fig. 3g, supernatant fraction, red arrows), while having
the lowest levels of envelope in the cell fractions. For prME, we
detected ZIKV envelope only in concentrated supernatant at 40 h
but not at 24 h after transfection, whereas the Env construct
containing the TM domain did not support secretion of the
antigen to the supernatant at these time points (Supplementary
Figs. 9, 11). These results suggest that antigen secretion in our
adenoviral vaccine platform is modulated by membrane-
anchoring components of the ZIKV structural proteins.
ZIKV-neutralising capacity in vaccinated mice sera. We tested
BALB/c mice sera obtained 4 and 16 weeks after a single
ChAdOx1 ZIKV vaccination to assess ZIKV antibody neu-
tralisation activity in vitro. The method we used is based on the
high-throughput microneutralisation (MN) assay described in
several studies that have evaluated the efﬁcacy of experimental
vaccines against ZIKV in mice and macaques9,16–18, as well as
in the validated neutralisation assay used for a phase 1 clinical
zika DNA vaccine7,19, and recently in three phase I clinical trials
of a puriﬁed inactivated ZIKV vaccine20, with small modiﬁca-
tions. Brieﬂy, 50–100 PFU of the Brazilian ZIKV-PE24321 strain
previously mixed with different threefold dilutions of mouse
serum (1:20–1:43 740) are incubated with Vero cells in a 96-well
format. After a 3-day incubation, cells are lysed and the levels of
ZIKV envelope protein from infected cells are quantiﬁed by
measurement of optical density using a highly sensitive sandwich
ELISA format. For the sandwich ELISA, a rabbit antiserum R34
was developed to recognise a region between a.a. 147 and 161 that
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manufacturers. c PBMCs–IFNγ-producing cells from DNA Prime-Boost after 2 weeks (left) and ChAdOx1 ZIKV vaccines at 2 weeks and 3 months after
single immunisation were quantiﬁed by ELISPOT. 20-mer peptides spanning the ZIKV envelope protein (10 μg/ml) were used for stimulation. Line colours
and shapes represent mice vaccinated with each vaccine. Antibody production by ELISA and cellular responses by ELISPOT were replicated three times in
the laboratory. A positive control sample was included to validate the ELISA assay
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04859-5
4 NATURE COMMUNICATIONS |  (2018) 9:2441 | DOI: 10.1038/s41467-018-04859-5 | www.nature.com/naturecommunications
is unique to each ﬂavivirus and that forms a conformational
exposed loop (Supplementary Fig. 6).
At 4 weeks post vaccination, sera from the ChAdOx1 prME
and ChAdOx1 prME ΔTM-vaccinated group showed neutralisa-
tion activity against ZIKV-PE243 with MN50s ranging from 114
to 432 and from 292 to 434, respectively (Fig. 4a). In comparison,
at 16 weeks after the ChAdOx1 ZIKV vaccination, MN50s were
surprisingly maintained at high levels in the prME ΔTM group
with MN50s ranging from 253 to 1600, while the ChAdOx1
prME showed lower MN50s of 30 to 89. These results indicate a
beneﬁcial effect of including the prM region as part of an
adenoviral vectored vaccine and it highlights the importance of
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deleting the 3′ TM region of the envelope to maintain good
memory responses. Virus neutralisation was also assessed in
outbred CD1 4 months after a ChAdOx1 ZIKV vaccination
(Supplementary Fig. 3c), showing that ChAdOx1 prME ΔTM
vaccine is able to induce MN50 values of 113 to 150, whereas
ChAdOx1 prME group showed MN50 values of 10.38 to 18.23.
Taken together, this conﬁrms that ΔTM is an important factor
to maintain neutralising antibody activity over longer periods
of time.
Lack of evidence of ADE to dengue 2 after ZIKV vaccination.
Next, we tested whether antibodies induced by ChAdOx1 prME
ΔTM vaccine cross-react with the envelope protein from all
dengue virus (DENV) serotypes (DENV1-4), by ELISA. Our
results indicated that ZIKV antibodies are able to bind DENV
(Fig. 4b). We then addressed the possibility of ADE to DENV
infection being induced by ZIKV vaccination, using a well-
established in vitro assay for ADE to DENV222 (Fig. 4c), as it is
the most difﬁcult serotype to protect against with the only
licensed dengue vaccine23,24 and the most suitable serotype to
address ADE in vitro. We assessed the ability of sera from
ChAdOx1 ZIKV-vaccinated mice groups to promote ADE in
the human myeloid cell line U937, which is less permissive
to infection by DENV in the absence of ADE22. DENV2 was pre-
incubated with a titration of mouse sera at 4 weeks after a
single immunisation with ChAdOx1 ZIKV vaccines, and the
DENV2-serum complex was used to infect U937 cells. As positive
controls, we used anti-DENV2 antibodies that leads to in vitro
ADE by DENV2 (Fig. 4c, top left and Supplementary Fig. 8) and
as a negative control we used sera from the ChAdOx1 control
vaccine (Fig. 4c, top right). None of the sera obtained from
ChAdOx1-vaccinated groups induced enhancement of DENV2
infection regardless presence or absence of TM, whereas there
was a 50-fold ADE increase when using an anti-DENV2 antibody
(Fig. 4c, bottom left and right). These results demonstrate that
antibodies raised to ZIKV in ChAdOx1 ZIKV-vaccinated mice
do not promote ADE of DENV2 in vitro despite cross-reacting
with envelope of all DENV serotypes.
Discussion
We have developed a ChAdOx1 ZIKV vaccine with the ability
to provide 100% protective efﬁcacy against a ZIKV-BR isolate.
In our hands, the addition of prM and deletion of TM from
ZIKV envelope are important factors in driving improved pro-
tective immunity, while promoting long-term memory responses
by enhancing and maintaining antibody production as well
as T-cell responses, when compared to previously reported
vaccines. Our vaccine design is different from the previously
published ZIKV vaccines7,9,10. Larocca et al.7 and
Abbink et al.9 showed that addition of the TM from envelope was
important to elicit full protective efﬁcacy in vaccines carrying a
Japanese encephalitis virus (JEV) leader sequence and a 93 a.a.
deletion of pr from prM. Importantly, the impact of ΔTM in the
immunogenicity and efﬁcacy was not assessed in the adenoviral
platform RhAd52-prM-Env, only in DNA-based vaccines. We
found that DNA vaccines showed differential immunogenicity
when compared to the adenoviral counterparts and hence the
importance of constructing four adenoviral vaccine candidates
and assessing their protective capabilities. Dowd et al.10 devel-
oped a DNA vaccine consisting of a JEV leader sequence followed
by a full prM and the full ZIKV envelope; or with a replacement
of the endogenous stem and TM from ZIKV with those from JEV,
however the authors did not assess the impact of the ΔTM.
Richner et al. have developed an mRNA-based vaccine in lipid
nanoparticles encoding the full prME of ZIKV and using a leader
sequence from the human IgE gene. Results from this mRNA-
based vaccine show that two doses elicited strong and protective
antibody responses15. Alternatively, Pardi et al.13 achieved
neutralising antibodies in a single intradermal dose with an
mRNA-based nanoparticle vaccine, this time using the full prME
from ZIKV, including a leader sequence from major histo-
compatibility complex (MHC) class II. However, neither of
the mRNA-based ZIKV vaccine studies assessed the impact of a
ΔTM deletion in their candidates to study its differential
immunogenicity. On the other hand, Kim et al.25 have reported
a protective two-dose regimen with a human adenoviral vaccine
(Ad5) encoding the prME of ZIKV with a deletion of envelope
transmembrane domain, being replaced with a T4 ﬁbritin foldon
trimerization domain, as well as a human leader sequence, both
to improve antigen secretion.
It has been shown that an optimal leader sequence is protein-
dependent26 and differences observed in these studies may be also
attributed to the use of alternative leader sequences (such as those
from JEV, MHCII and IgE). We have used a non-viral leader
sequence (tissue plasminogen activator; tPA)27, which has been
used safely in humans for many vectored vaccines28 and which is
unlikely to induce responses in humans29. Regarding previous
vaccine developments, it is important to take into account pre-
existing humoral and cellular cross-reactive immune responses to
human adenovirus; as well as when using JEV sequences to
improve antigen secretion (leader sequence and/or JEV trans-
membrane domains), as they might have a detrimental effect on
the efﬁcient ZIKV antigen production, i.e., Asian populations
exposed to or vaccinated against JEV. Moreover, different vaccine
platforms such as DNA, mRNA-based vaccines, VLPs or ade-
noviral vectors, ZIKV strains used for the immunogen design, as
well as different routes of administration may also account for
different immunogenicity and efﬁcacy levels achieved. In this
study, we have used a non-lethal challenge model in BALB/c mice
and we have measured vaccine efﬁcacy by means of partial or
complete reduction of viraemia by PCR. However, we do not rule
out the possibility of ZIKV presence in key organs such as brain,
liver, spleen, reproductive tract, etc. Further studies, such as the
Fig. 3 Assessment of protective efﬁcacy induced by ChAdOx1 ZIKV vaccines. a BALB/c mice (n= 5) immunised with a single i.m. injection of ChAdOx1
ZIKV vaccines and naive mice were intravenously challenged with 105 VP of ZIKA-BR at week 4 after prime. Pre-challenge serum samples were collected
for ELISA as shown. b Viral load in ZIKV-challenged groups was monitored for 7 days in sera to follow the onset of viraemia. Each blue line represents one
mouse. c Assessment of various parameters of viraemia in groups vaccinated with ChAdOx1 ZIKV vaccines (100%= 6 out of 6 mice). d Pre-challenge
reciprocal ELISA titres (Supplementary Fig. 4) were plotted against global ZIKV VL after ZIKV challenge and a comparison was made between ChAdOx1
Env ΔTM versus ChAdOx1 prME ΔTM (left) and ChAdOx1 prME versus ChAdOx1 Env (right). e ELISA OD 450 reads of serially diluted serum samples
were plotted to assess the impact of ΔTM in antibody production. Antibody production by ELISA in pre-challenge sera was replicated two times.
f Immunoﬂuorescence analysis of Vero cells expressing the ZIKV immunogens (green) to assess subcellular staining and distribution. Antigen was
detected using a commercial anti-ﬂavivirus antibody. Blue (DAPI) represents the nucleus and scale bar is 20 μm. Cell transfections were performed in
technical duplicates in two biological replicates. g Kinetics of ZIKV envelope antigen expression in HEK-293 cells by western blot. Antigen was detected
using an anti-ZIKV monoclonal antibody in both, non-concentrated supernatant and cell extracts. Red arrows, ZIKV envelope. Actin was used as a loading
control. Expression of antigen was veriﬁed in three biological replicates. Uncropped blots are shown in Supplementary Fig. 5
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use of a highly susceptible ZIKV challenge model in A129 mice,
are needed to explore ZIKV presence in those organs after a
single and non-adjuvanted ChAdOx1 ZIKV vaccination. Another
correlate of vaccine efﬁcacy is assessing the ZIKV neutralisation
of sera from vaccinated mice in vitro. For this we have used a MN
assay, highly similar to that performed in phase I clinical trials of
several Zika vaccines in the pipeline20,30,31. Furthermore, MN is a
validated assay used previously in several publications to assess
ZIKV vaccine efﬁcacy in mice and non-human primates9,16–18,
as well as other ﬂaviviruses19. Other neutralisation assays,
such as traditional PRNT50, FRNT50 and reporter viral
particle assay (using green ﬂuorescent protein, Luciferase and
mCherry as reporters) have also proven to be suitable. However,
it is challenging to perform an accurate comparison of vaccine
efﬁcacy between other reported vaccine candidates, as neu-
tralisation 50 (NT50) titres vary from one assay to another (dif-
ferent ZIKV strains, different ZIKV puriﬁcation methodologies
and different cell lines [i.e., Vero and BHK-2] and different
detection methods). Nonetheless, we have performed a fair head-
to-head comparison between our high-throughput MN assay
versus a traditional PRNT assay. Our results demonstrate that our
MN assay is more stringent at detecting ZIKV infection than
PRNT (Supplementary Fig. 3d). Therefore, the MN50 values in
our study are moderate when compared to PRNT. Similar
observation has been reported by Dowd et al.10 in which MN50
titres are actually lower than those of a parallel FRNT50 assay.
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Fig. 4 ZIKV neutralisation assay and antibody-dependent enhancement (ADE) to DENV2 infection. a Microneutralisation titre 50 (MN50) assay in Vero
cells was assessed upon incubation of ZIKV-BR in the presence of serially diluted sera from BALB/c mice vaccinated with ChAdOx1 ZIKV vaccines at
4 weeks and 4 months. Results show the average of three biological replicates, with duplicates and black lines represents the mean (n= 6). A two-way
ANOVA followed by Sidak’s Multiple comparison was performed. ****p < 0.0001, ***p < 0.0003. Supplementary Table 1 shows the multiple comparison
between all the groups. b ELISA cross-reactivity of DENV1-4 in sera from mice vaccinated with the highly protective ChAdOx1 prME ΔTM vaccine. Bars
represent the average and error is the s.d. c Infection of U937 cells by a DENV2 strain in the presence of sera from mice vaccinated with ChAdOx1 ZIKV
candidates. Infection enhancement fold was calculated as the ratio of focus-forming units (FFU) of an anti-DENV2 monoclonal antibody to that of the FFU
in the presence of serial dilutions of mouse sera collected 4 weeks after ChAdOx1 ZIKV vaccination. Each coloured line and shape represents a mouse for
each group. n= 6/vaccinated group. Data represent three technical replicates, with a positive control anti-DENV2 antibody
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However, MN assays together with ZIKV challenge models are
both highly informative to efﬁciently down-select Zika vaccine
candidates in the preclinical setting.
The risk of inducing ADE32, a process in which vaccine- or
infection-induced cross-reactive antibodies facilitate DENV
infections33 by promoting viral entry via Fcγ receptors, adds
another level of complexity in the design of a safe and efﬁcacious
ZIKV vaccine. ZIKV and DENV co-circulate in endemic
regions making ADE a concern as it is not known whether
antibodies elicited by ZIKV vaccines may in turn exacerbate
other ﬂaviviral infections such as dengue. A protective vaccine
that does not induce ADE while providing long-lasting immunity
to ZIKV would be a major breakthrough to halt the epidemics.
Here we demonstrate that anti-ZIKV antibodies did not induce
ADE to DENV2 upon immunisation with ChAdOx1 ZIKV
vaccines in vitro. In this study, we incubated mouse sera with
ZIKV and then inoculated this mixture onto human U937 cells
expressing a human Fc receptor. Although we have reacted
the mouse monoclonal antibody (mAb; 4G2) with DENV2 and
observed the ADE phenomena in human U937 cells (Supple-
mentary Fig. 7), it is possible that mouse Fc could present a
degree of incompatibility with the human Fc receptor in U937
cells. Additional in vivo experiments should be carried out to
completely rule out any enhancing effect of anti-ZIKV antibodies
to DENV. In vitro ADE to ZIKA virus has been demonstrated in
human sera positive for DENV that cross-reacted with ZIKV22.
Richner et al.15 have also shown that a mutation of the fusion
loop of ZIKV envelope decreased the risk of ADE to DENV2 in
their mRNA-based vaccines in vitro. A recent study, interestingly,
shows that DENV antibodies did not increase viremia and disease
after a ZIKV challenge in macaques, although ADE to ZIKV was
detected in vitro34. Similarly, cross-reactive human mAbs by
ZIKV or DENV directed primarily and cross-reactive to EDI/II
can mediate heterologous ADE, while in vivo observations indi-
cate that the same cross-reactive anti-ZIKV mAbs can lead to
ADE and enhance infection by DENV, while the opposite effect
for ZIKV ADE does not take place35. Therefore, assessing ADE
both in vitro and in vivo should be taken into account and
mechanistically explored in current and ongoing ZIKV vaccine
developments.
Chimpanzee adenovirus vaccine platforms such as ChAdOx1
offer a good safety proﬁle in phase I clinical trials in humans36–40;
efﬁcient biomanufacture of millions of doses of non-replicating
adenoviral vectors is possible using GMP-approved cell lines.
They avoid pre-existing immunity to human adenoviruses, and a
single non-adjuvanted dose of ChAdOx1 is enough to achieve
remarkable breadth, durability and potency of both humoral and
cellular immune responses. A ChAdOx1 ZIKV vaccine engi-
neered to positively impact immune responses over longer peri-
ods of time, by means of deletion of membrane anchors, is a valid
platform to be explored in further clinical trials.
Methods
Animals. Female inbred BALB/c (H-2d) and outbred CD1 (ICR) mice (6–8 weeks)
were used for the assessment of immunogenicity (n= 6 mice/group). ZIKV chal-
lenge was performed in BALB/c mice (n= 5/group). Mice were purchased from
Envigo (UK) and from Charles River (USA). The experimental design took into
account the 3R reduction (replacement, reduction and reﬁnement). No randomi-
sation was used in this work.
Immunisation of mice. For DNA vaccines encoding the ZIKV virus antigens, mice
received a prime of 100 µg of DNA vaccine/mouse in endotoxin-free phosphate-
buffered saline (PBS); 2 weeks after the prime a boost injection was preformed
using the same concentration of DNA vaccine. For adenoviral vaccines, mice were
vaccinated with a single dose of chimpanzee adenoviral vectored vaccine (ChA-
dOx1) encoding the ZIKV antigens at a dose of 1 × 108 infectious units. All DNA
vaccines and viral vector vaccines were administered intramuscularly and diluted
in endotoxin-free PBS. Empty DNA vaccine and a ChAdOx1 expressing an
unrelated malarial antigen (cCSP) were used as control vaccines.
Ethics statement. All animals and procedures were used in accordance with the
terms of the UK Home Ofﬁce Animals Act Project License. Procedures were
approved by the University of Oxford Animal Care and Ethical Review Committee
(PPL 30/2414). Animal experiments performed at Harvard were approved by the
BIDMC Institutional Animal Care and Use Committee.
Bioinformatics analysis of ZIKV genomes and proteins. Complete ZIKV gen-
omes deposited in the GenBank in November 2015 (no less than 10.5 kb) were
used to construct a phylogenetic tree, which allowed us to further identify
and design our vaccine transgene candidates. Further phylogenetic trees were
built for genome sequences deposited in the gene bank between April and
October 2016. Alignment analysis for both nucleotides and protein sequences,
consensus analysis and phylogenetic trees were produced by focusing only in the
structural and non-structural coding sequences. Geneious software was used to
generate the phylogeny trees using a Neighbour-Joining method. Sequence align-
ments between zika, dengue and yellow fever proteins allowed us to annotate the
ZIKV consensus sequences generated in November 2015 using the following fea-
tures (start codon, transmembrane domains and known ﬂaviviruses enzymatic
cleavage sites).
Transgene design. For the Asian Lineage vaccine design, prM and envelope
coding sequence (translated to 670 a.a.) from the Asian ZIKV consensus sequence
was codon optimised, and a tPA leading nucleotide sequence was added before
the 5′ end of prM. To improve initiation of translation a Kozak consensus
sequence was included before the 5′ end of tPA. Finally, the transgene design
included the required enzymatic restriction sites to allow the in-frame cloning
of the transgene between the cytomegalovirus (CMV) promoter and the polyA
sequence region contained in our shuttle and expression vector (pMono). Synthetic
gene cassette was produced by GeneArt® and was named prME.
The GeneArt® prME plasmid was used as template to further generate the
following versions by PCR subcloning, including restriction sites, stop codons or
other features as follows:
-prME with the TM domain of envelope deleted (prME ΔTM):
Forward primer AGAAGAGGATCGAAGCTTGCCATCACCAGAAGAGGCA
GCG
Reverse primer GCATGCTCGAGCGGCCGCTCATCACATTCTCTTGGCTC
CCCGC
-Full envelope (Env):
Forward primer GAAACCGGTAAGCTTATGCGGTGTATCGGCGTGTCC
Reverse primer ACCGGTCAGACGTACTCGA
-Envelope with TM deleted (Env ΔTM):
Forward primer GAAACCGGTAAGCTTATGCGGTGTATCGGCGTGTCC
Reverse primer CACCAATGCGGCCGCCTCGAGCTATTACAGAGAGTTCA
GGGCTCCG
DNA vaccine production. The prME and prME ΔTM were digested with KpnI
and NotI to allow in-frame ligation between the CMV promoter and the poly(A)
regions contained in the DNA vaccine plasmid (pMono). The remaining PCR-
subcloning transgenes (Env and Env ΔTM) were digested with AgeI and NotI to
allow in-frame ligation between the tPA leader sequence and the poly(A) regions of
pMono. pMono was digested accordingly to generate the following DNA vaccines:
pMono prME; pMono prME ΔTM; pMono Env; and pMono Env ΔTM. Zika DNA
plasmid vaccines were expanded in Escherichia coli and Endo-free Giga Prep
(Qiagen) was used for plasmid puriﬁcations. DNA vaccines were veriﬁed by
restriction analysis and 5′ and 3′ ﬂanking sequencing. In addition, DNA vaccines
were transfected in HEK-293 and Vero cells to verify the correct expression of the
transgenes.
Adenoviral Zika vaccine production. All of the DNA constructs required for
ChAdOx1 were cloned in two steps. In the ﬁrst step, unique KpnI and NotI sites
were used to insert the synthetic transgenes into an adenovirus entry plasmid. The
transgene was placed upstream of BGH poly(A) transcription termination
sequence and under the control of the CMV promoter. The entry plasmid con-
taining attL regions sequences was recombined with those attR regions contained
in the destination vector ChAdOx1 using an in vitro Gateway reaction (LR Clonase
II system, Invitrogen). Successfully recombined ChAdOx1 ZIKV plasmids were
veriﬁed by DNA sequencing using ﬂanking primers (promoter forward primer and
poly-(A) reverse primer). Standard cell biology and virology techniques were
performed to generate the non-replicative adenoviral vectors36.
Cell culture. HEK-293 and Vero cells (ATCC®, CRL-1573TM and ATCC
CCL81TM, respectively) were grown in Dulbecco’s modiﬁed Eagle’s media
(DMEM) supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% non-
essential amino acids. Cell number and viability were calculated by trypan blue
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04859-5
8 NATURE COMMUNICATIONS |  (2018) 9:2441 | DOI: 10.1038/s41467-018-04859-5 | www.nature.com/naturecommunications
staining using the Countess Automated Cell Counter (Life Technologies). Both cell
lines are described in the NCBI Biosample database.
Immunoﬂuorescence microscopy. Transfected Vero cells grown on coverslips
were ﬁxed in 4% paraformaldehyde in 1× PBS (10 min, room temperature), per-
meabilised in 0.1% PBS-Triton X-100 for 20 min at room temperature (RT) and
blocked in 2.5% goat serum/0.5% bovine serum albumin (BSA) in PBS for 45 min
at RT. The primary antibody (anti-ﬂavivirus group antigen D1-4G2-4-15, 1/250,
Merck Millipore) was diluted in 1% BSA in PBS and incubated with samples for 1 h
at RT. After successive washes in PBS, secondary antibody coupled to Alexa Fluor
488 was added for 1 h at RT in the dark. Samples were washed in PBS with a last
wash in distilled water and mounted in Prolong-DAPI mounting reagent (Life
Technologies). Cells were acquired on a LSM 880 inverted confocal microscope
using Zen 2.1 software (Zeiss). Images were analysed using ImageJ software
(National Institutes of Health).
Western blot analysis. Cells were washed twice with ice-cold PBS and harvested
in cold 1× PBS. 1× and 4× Laemmli buffer were added to cells and supernatants,
respectively, and boiled at 100 °C for 5 min. Equal amounts of total cell extracts and
15 μl of cell supernatants were resolved by SDS/PAGE and transferred to poly-
vinylidene ﬂuoride membranes. In some cases, supernatants were 10× concentrated
using Amicon Ultra-0.5 ml centrifugal ﬁlters. Blots were blocked with 1× PBS-
Tween-5% milk and incubated with anti-ZIKV envelope seropositive mice sera
(1:500) or a mAb versus ZIKV envelope (AZ1176, Clone 0302156), Aalto Bio
Reagents), followed by incubation with horseradish peroxidase (HRP)-conjugated
secondary antibody (1:5000). Chemiluminescence (Perkin-Elmer Life Sciences,
Boston, MA) was visualised using the BioRad ChemiDoc SRS device. Uncropped
images of the blots are shown in Supplementary Figs. 2, 5, 9, 10 and 11).
Whole IgG ELISA. RecombivirusTM mouse anti-ZIKV envelope protein IgG
ELISA kits (Alpha Diagnostic International, RV-403120-1) were used under the
manufacturer protocol. Brieﬂy, 96-well plates coated with ZIKV envelope protein
were equilibrated with 300 μl of kit working wash buffer. Serial dilutions (threefold)
of sera from vaccinated mice were added. Diluted sera were incubated at RT for 1 h,
and after four times washing buffer incubations, 100 μl/well of anti-mouse IgG
HRP conjugate working solution was added for 30 min at room temperature. Plates
were washed ﬁve times and developed 15 min at room temperature with 100 μl of
tetramethyl benzidine (TMB) substrate, then stopped by the addition of 100 μl of
stop solution. Absorbance was measured at 450 nm on a microplate reader. ELISA
optical densities (ODs) were compared between all vaccinated groups at different
sera dilutions. Alternatively, a relative positive index was calculated following the
manufacturer RecombivirusTM Mouse Anti-Zika virus ELISA kit. Brieﬂy, positive
index was calculated by the OD mean plus two times the s.d. of the control/naive
sera. Then, we divided the OD of each sample by the positive index. Values below 1
are considered negative and values above 1 are considered positive. Relative
positive index then was plot for every vaccinated mouse per group.
For pre-challenge ELISA, endpoint titres were deﬁned as the highest reciprocal
serum dilution that yielded an absorbance greater than twofold over background
values, as calculate elsewhere8–10.
DENV1-4 ELISA: Dengue Env-2 45 kDa (Den021), Dengue Env-1 45 kDa
(Den022), Dengue Env-3 45 kDa (Den023) and Dengue Env-4 45 kDa (Den024)
from Dundee Cell Products Ltd. were used to coat Maxisorp NUNC 96-well plates
(2 μg/ml) and ELISAs performed to determine the reciprocal titre of the sera
dilution.
Ex vivo IFNγ ELISPOT assay. ELISPOTs were carried out using peripheral blood
mononuclear cells (PBMCs) isolated from the blood. Brieﬂy, MAIP ELISPOT
plates (Millipore) were coated an anti-mouse IFNγ mAb, after 1 h blocking with
complete DMEM media (10% fetal calf serum). Isolated PBMCs (using ACK buffer
solution) were plated alongside with 20-mer speciﬁc peptides overlapped by 10 a.a.
(10 μg/ml) and 2.5 × 105 splenocytes from naive mice per well. After 16 h incu-
bation, cells were discarded and plates washed with PBS. Following this, 50 μl of
biotinylated anti-mouse IFNγ mAb (1:1000 in PBS) was added to each well and
incubated for 2 h. After washing, plates were incubated with 50 μl of ALP (1:1000
in PBS) reagent for 1 h. After another washing step, developing solution (BIORAD)
was used. Once spots were visible, the reaction was stopped by washing plate off
with water. Spots were acquired using an ELISPOT reader. Spot-forming cells/106
PBMCs producing IFNγ were calculated.
ZIKV challenge model. ZIKV challenge was performed as described7. Brieﬂy,
naive and vaccinated BALB/c mice (n= 5/group) were infected at week 4 post
immunisation by the intravenous route with 105 viral particles (102 PFU) of ZIKV-
BR. VLs following ZIKV challenge were quantitated by RT-PCR at days 1, 2, 3, 4
and 7. Sample size was determined to achieve 80% power to detect signiﬁcant
differences in protective efﬁcacy. Vaccines were administered in a blind experi-
ment. After the experimental outcome of the ZIKV challenge and the pre-challenge
ELISAs, samples were decoded.
Revese transcription-PCR. VLs were assessed as depicted7. Brieﬂy,
RNA was extracted from serum with a QIAcube HT (Qiagen). RNA was
puriﬁed using the RNA clean and concentrator kit (Zymo Research), and
RNA quality and concentration was assessed by the BIDMC Molecular Core
Facility of Harvard University. Log dilutions of the RNA standard were reverse-
transcribed and included with each RT-PCR assay. VLs were calculated as
virus particles/ml. Assay sensitivity was 100 copies/ml. The infectivity of virus
in peripheral blood from ZIKV-challenged mice was conﬁrmed by PFU assays.
Speciﬁc primers were used to amplify a region contained in the Capsid of the ZIKV
genome.
Polyclonal anti-ZIKV E antiserum R34. We identiﬁed a short region
(a.a. 147–161) around the N154 glycosylation site of the envelope protein that is
unique to each ﬂavivirus and that forms an exposed loop (the so called 150 loop)
on the surface of the envelope protein (Supplementary Fig. 6a, b), and then raised a
rabbit antiserum (R34) to it which speciﬁcally recognised the ZIKV envelope
protein (Supplementary Fig. 6c). A peptide corresponding to amino acid residues
144–166 of ZIKV envelope (HGSQHSGMIVNDTGHETDENRAK) with an
additional C-terminal cysteine residue was synthesised by Isca Biochemicals (UK)
and directionally conjugated to keyhole limpet haemocyanin (KLH) using
maleimide chemistry. Two rabbits were immunised with the peptide-KLH
conjugate combined with Freund’s adjuvant, following a standard protocol. This
work was carried out by Dundee Cell Products (UK). The immune sera were tested
by western blot, ELISA and IF for speciﬁc reactivity with ZIKV E protein, and R34
was selected as the better antiserum. Total IgG was puriﬁed from R34 antiserum by
protein G afﬁnity chromatography.
ZIKV MN assay. Vero cells were seeded in 96-well plates at 7 × 103/well and
incubated at 37 °C in 5% CO2 for 1 day to form a subconﬂuent monolayer. Ali-
quots of Brazilian ZIKV-PE24321 at 100 PFU in 15 µl were mixed with an equal
volume of twofold dilutions of sera in medium and incubated at 37 °C for 1 h. The
cells were infected with the serum/virus mixture (30 µl/well), incubated at 37 °C for
1 h, and then 100 µl of medium was added to each well. At day 3 post infection,
cells were lysed in lysis buffer (20 mM Tris-HCl [pH 7.4], 20 mM iodoacetamide,
150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100 and Complete™ protease inhibi-
tors) and the viral E protein quantitated by sandwich ELISA (below). The amount
of envelope detected correlates with the level of virus infectivity. Values
representing % of ZIKV infectivity relative to the control (i.e., virus not pre-
incubated with immune sera) were plotted using Graphpad Prism 6, and nonlinear
regression (curve ﬁt) performed for the data points using Log (inhibitor) versus
response (variable slope) to determine MN50 titres. The MN50 titre was deﬁned as
the serum dilution that neutralised >50% of ZIKV. This format resulted in a very
robust MN assay, with a signal-to-noise ratio of >10 and a Z-factor of 0.8, which
is optimal value for high-throughput screening assays. A comparison between
our MN assay versus a traditional PRNT assay41 was performed, using a series
of twofold dilutions of a highly potent monoclonal neutralising antibody to
ZIKV (EDE1 C8)42.
Sandwich ELISA to assess ZIKV infectivity. Immulon 2 HB plate (Thermo
Scientiﬁc™) 96-well plates were coated with 3 µg/well of puriﬁed pan-ﬂavivirus
MAb D1-4G2-4-15 (ATCC® HB112TM) in PBS and incubated overnight at RT. The
antibody was removed and the wells blocked for 2 h at RT with 2% skimmed milk
powder in PBS containing 0.02% Tween-20 (PBST). After washing with PBST,
ZIKV-infected cell lysates were added and incubated for 1 h at RT. Wells were
washed with PBST, incubated with R34 IgG at 6 µg/ml in PBST for 1 h at RT and
washed again. The antibodies bound to ZIKV envelope protein were detected using
anti-rabbit HRP conjugate (Abcam) and TMB (Sigma) substrate. Absorbance at
450 nm was measured in a microplate reader.
In vitro assessment of ADE. Serially diluted mAb or mice sera samples were
incubated with virus DENV2 strain 16681, Moi= 2 for 1 h at 37 °C before adding
to U937 cells. After 3-day incubation, supernatants were harvested and viral
titres determined by focus-forming units. Fold enhancement was calculated by
comparison to viral titres in the presence or absence of antibody22. Antibodies used
as positive control are mouse anti-Flavivirus envelope protein antibody (4G2) and
anti-envelope dimer Epitope 1 [752-2C8].
Statistics. Graphing and statistical analysis were performed using GraphPad
Prism version 7.00 for Mac, GraphPad Software, La Jolla California USA,
www.graphpad.com. For pre-challenge ELISA, the analysis used was the one-
way analysis of variance (ANOVA), followed by Turkey’s multiple
comparisons test. For the ZIKV neutralisation assay, a two-way ANOVA
followed by Sidak’s multiple comparison was performed. All graphs were plotted
with bars and errors, representing the mean and the s.d. Assumptions of data are
normal distribution, homogeneity, independent and groups must have same
sample size.
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Data availability. The authors declare that the data supporting the ﬁndings of this
study are shown in the article and in the Supplementary section and are available
from the authors upon request.
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